Last Updated : February 5, 2025
Details
FilesGeneric Name:
olopatadine hydrochloride and mometasone
Project Status:
Active
Therapeutic Area:
Seasonal allergic rhinitis
Manufacturer:
Bausch Health
Call for patient/clinician input open:
Brand Name:
Ryaltris
Project Line:
Reimbursement Review
Project Number:
SR0848-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Ryaltris (olopatadine hydrochloride and mometasone furoate nasal spray) is indicated for the symptomatic treatment of moderate to severe seasonal allergic rhinitis (SAR) and associated ocular symptoms in adults, adolescents, and children aged 6 years and older.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
For the symptomatic treatment of moderate to severe seasonal allergic rhinitis (SAR) and associated ocular symptoms in adults, adolescents, and children aged 6 years and older.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | May 10, 2024 |
|---|---|
| Call for patient/clinician input closed | July 08, 2024 |
| Submission received | June 21, 2024 |
| Submission accepted | July 08, 2024 |
| Review initiated | July 09, 2024 |
| Draft CADTH review report(s) provided to sponsor for comment | September 26, 2024 |
| Deadline for sponsors comments | October 08, 2024 |
| CADTH review report(s) and responses to comments provided to sponsor | November 15, 2024 |
| Expert committee meeting (initial) | November 27, 2024 |
| Draft recommendation issued to sponsor | December 09, 2024 |
| Draft recommendation posted for stakeholder feedback | December 19, 2024 |
| End of feedback period | January 10, 2025 |
| Expert committee meeting | March 26, 2025 |
Files
Last Updated : February 5, 2025